These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
64. The use of Gene Ontology terms and KEGG pathways for analysis and prediction of oncogenes. Xing Z; Chu C; Chen L; Kong X Biochim Biophys Acta; 2016 Nov; 1860(11 Pt B):2725-34. PubMed ID: 26801878 [TBL] [Abstract][Full Text] [Related]
65. Control of oncogene expression by antisense nucleic acids. Hélène C Eur J Cancer; 1994; 30A(11):1721-6. PubMed ID: 7833151 [No Abstract] [Full Text] [Related]
66. [Function of oncogenes in neuroepithelial tumors]. Diedrich U Fortschr Neurol Psychiatr; 1992 Apr; 60(4):146-53. PubMed ID: 1601384 [TBL] [Abstract][Full Text] [Related]
67. Blocking oncogenic Ras signaling for cancer therapy. Adjei AA J Natl Cancer Inst; 2001 Jul; 93(14):1062-74. PubMed ID: 11459867 [TBL] [Abstract][Full Text] [Related]
68. Deciphering oncogenic drivers: from single genes to integrated pathways. Chen J; Sun M; Shen B Brief Bioinform; 2015 May; 16(3):413-28. PubMed ID: 25378434 [TBL] [Abstract][Full Text] [Related]
69. Genetic modulation in the pathogenesis and treatment of cancer. Casson AG; McCart JA Chest Surg Clin N Am; 1995 Feb; 5(1):17-37. PubMed ID: 7743146 [TBL] [Abstract][Full Text] [Related]
70. Oncogenic Activities of IDH1/2 Mutations: From Epigenetics to Cellular Signaling. M Gagné L; Boulay K; Topisirovic I; Huot MÉ; Mallette FA Trends Cell Biol; 2017 Oct; 27(10):738-752. PubMed ID: 28711227 [TBL] [Abstract][Full Text] [Related]
71. [Outline of the tumorigenesis of brain tumors]. Maruno M; Yoshimine T; Hayakawa T Nihon Rinsho; 2005 Sep; 63 Suppl 9():19-23. PubMed ID: 16201494 [No Abstract] [Full Text] [Related]
73. A stochastic model of oncogene expression and the relevance of this model to cancer therapy. Alfano FD Theor Biol Med Model; 2006 Jan; 3():5. PubMed ID: 16448558 [TBL] [Abstract][Full Text] [Related]
74. DNA damage signalling guards against activated oncogenes and tumour progression. Bartek J; Bartkova J; Lukas J Oncogene; 2007 Dec; 26(56):7773-9. PubMed ID: 18066090 [TBL] [Abstract][Full Text] [Related]
76. [Cancer genetics. A review of oncological molecular biology seen in relation to the human genome]. Gerdes AM Ugeskr Laeger; 2002 May; 164(22):2865-71. PubMed ID: 12082811 [TBL] [Abstract][Full Text] [Related]
77. MDM2 oncogene as a novel target for human cancer therapy. Zhang ; Wang H Curr Pharm Des; 2000 Mar; 6(4):393-416. PubMed ID: 10788589 [TBL] [Abstract][Full Text] [Related]
78. Chromatin dependencies in cancer and inflammation. Marazzi I; Greenbaum BD; Low DHP; Guccione E Nat Rev Mol Cell Biol; 2018 Apr; 19(4):245-261. PubMed ID: 29184195 [TBL] [Abstract][Full Text] [Related]
79. Melanoma genetics: the other side. Bis S; Tsao H Clin Dermatol; 2013; 31(2):148-55. PubMed ID: 23438378 [TBL] [Abstract][Full Text] [Related]
80. Tyrosine kinases as molecular targets to inhibit cancer progression and metastasis. Cepero V; Sierra JR; Giordano S Curr Pharm Des; 2010; 16(12):1396-409. PubMed ID: 20166985 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]